Bliss GVS Pharma Ltd (BLISSGVS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Bliss GVS Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 29 Oct 2026, 11:14 pm
Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss ....
Others (Uncategorized) · 29 Oct 2026, 10:52 pm
Bliss GVS Pharma Grants 295,000 ESOPs at Rs. 43 per Share Bliss GVS Pharma’s Nomination and Remuneration Committee granted 2,95,000 stock options under its ESOP Plan 2019 on 29th Oct'26, convertible into an equivalent number of equity shares with a face value of Re. 1 each. The options carry an exercise price of Rs. 43 per share, based on BSE's closing price on 28th Oct'26. Vesting is scheduled equally at 25% annually over four years, exercisable within six months of vesting. Shares allotted post-exercise will face a six-month lock-in period.
Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026
Outcome · 29 Oct 2026, 10:49 pm
Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026
Outcome · 29 Oct 2026, 10:47 pm
Please find attached the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Financial Result · 29 Oct 2026, 10:30 pm
Bliss GVS Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 31,337 (+28.2% YoY | +9.7% QoQ) ■ EBITDA: 8,058 (+85.3% YoY | +5.5% QoQ) ■ EBITDA Margin (%): 25.7 (+793 bps YoY | -104 bps QoQ) ■ PAT: 5,225 (+91.7% YoY | +4.3% QoQ) ■ EPS (INR): 4.81 (+89.4% YoY | +3.4% QoQ)
Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 29 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 29 Oct 2026, 5:30 am
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Intimation · 29 Oct 2026, 5:30 am
Bliss GVS Pharma Schedules Board Meeting for Q2 FY27 Financial Results Bliss GVS Pharma Limited announced that its Board of Directors will meet on 29th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed for designated persons and their immediate relatives from 1st Oct'26 and will remain shut until 48 hours post-declaration of the financial results.
We would like to inform you that the ESOP Allotment Committee at its meeting held today i.e. October 15, 2026 has approved the allotment of 53,500 equity shares of the face value of Re ....
Others (Uncategorized) · 15 Oct 2026, 10:59 pm
Bliss GVS Pharma Allots 53,500 Equity Shares Under ESOP 2019 Bliss GVS Pharma Limited's ESOP Allotment Committee approved the allotment of 53,500 equity shares of face value Re. 1 each on 15th Oct'26 under the Bliss GVS ESOP-2019 scheme at an exercise price of Rs. 43 per share (including a Rs. 42 premium). Consequently, the company's paid-up equity share capital increased from Rs. 10,63,30,473 (10,63,30,473 shares) to Rs. 10,63,83,972 (10,63,83,972 shares). The allotted shares rank pari passu with existing equity and carry a six-month lock-in expiring on 14th Apr'27.
Please find enclosed herewith the disclosure under Regulation 31A (10) of the SEBI Regulations in relation to re-classification from the "promoter and promoter Group category" to the "public" category
Others (Uncategorized) · 15 Oct 2026, 12:10 am
Anupam Rasayan India Acquires Control of Bliss GVS Pharma Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited have acquired control of Bliss GVS Pharma Limited following the consummation of the Share Purchase Agreement dated 23rd May'26 and the completion of the open offer. Effective 28th Sep'26, both acquirers have been classified as Promoters of the company, alongside 13 affiliated entities added to the Promoter Group. Consequently, the company's Board took note of the reclassification of the erstwhile Promoters and Promoter Group to the "Public" category under SEBI regulations.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Acquisition/ Disposal of Shares · 06 Oct 2026, 3:56 pm
Catalyst Trusteeship Acquires 47.95% Share Pledge in Bliss GVS Pharma Catalyst Trusteeship Limited, acting as debenture trustee on behalf of debenture holders, acquired an encumbrance via pledge over 5,09,84,595 equity shares of Bliss GVS Pharma Ltd on 30th Sep'26. The transaction represents 47.95% of the company's total voting capital and 46.77% of its total diluted share capital. Prior to this event, the acquirer held no shares or voting rights in the target company. Bliss GVS Pharma's total equity base stands at 10,63,30,472 shares, with a diluted capital base of 10,90,11,222 shares.
Please find enclosed herewith the outcome of the Board Meeting held today i.e. Thursday, October 01, 2026 through Video Conferencing or Other Audio Visual Means.
Outcome · 02 Oct 2026, 1:16 am
Bliss GVS Pharma Board Approves Two New ESOP Schemes Bliss GVS Pharma’s board approved the adoption of the Senior Executive ESOP 2026 and Employee ESOP 2026 on 1st Oct'26, subject to shareholder approval. The Senior Executive ESOP 2026 covers up to 26,50,000 equity shares (~2.49% of paid-up equity), while the Employee ESOP 2026 covers up to 47,00,000 equity shares (~4.42% of paid-up equity) on a fully diluted basis. Both schemes carry a fixed discounted exercise price of INR 10 per share with a minimum one-year vesting period.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anupam Rasayan India Ltd
Acquisition/ Disposal of Shares · 01 Oct 2026, 2:31 pm
Anupam Rasayan and PAC Acquire Controlling 50.07% Stake in Bliss GVS Pharma Anupam Rasayan India Limited and Person Acting in Concert (PAC), Mates Visa Consultancy Private Limited, acquired 5,09,84,595 equity shares (47.95% stake) in Bliss GVS Pharma Limited on 28th Sep'26 via a Share Purchase Agreement. Following this acquisition alongside earlier open-offer and on-market purchases, their combined holding reached 5,32,36,264 equity shares, representing 50.07% of total voting capital (48.84% diluted). Consequently, Anupam Rasayan and PAC have assumed control over Bliss GVS Pharma and become promoters of the target company effective 28th Sep'26.
BLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 01-Oct-2026 to consider ESOP.
Intimation · 30 Sept 2026, 4:50 pm
To consider Fund Raising and other business matters
Intimation · 29 Sept 2026, 2:32 am
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/10/2026 ,inter alia, to consider and approve Please find enclosed herewith ....
Intimation · 29 Sept 2026, 2:32 am
Bliss GVS Pharma Board to Consider ESOP Schemes on 1st Oct'26 Bliss GVS Pharma Ltd. announced that a meeting of its Board of Directors is scheduled for 1st Oct'26 via video conferencing. The board will convene to consider and approve proposals for the establishment of the Senior Executive Employee Stock Option Plan 2026 and the general Employee Stock Option Plan 2026, pursuant to Regulation 29 of SEBI LODR Regulations.
Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of the 2nd Board Meeting held on September 28, 2026 at shorter Notice regarding re-classification from the "Promoter and Promoter Group" category to the "public" category.
Outcome · 29 Sept 2026, 2:25 am
Please find enclosed herewith the Outcome of the 2nd Board Meeting held on September 28, 2026 at shorter Notice regarding re-classification from the "Promoter and Promoter Group" category ....
Outcome · 29 Sept 2026, 2:23 am
Bliss GVS Pharma Completes Ownership Transition and Promoter Reclassification Bliss GVS Pharma’s Board approved the reclassification of its outgoing promoter group to the "public" category on 28th Sep'26, following the consummation of the SPA dated 23rd May'26 and completion of the mandatory open offer. Anupam Rasayan India and PAC (Mates Visa Consultancy) acquired control, reducing the outgoing promoter group's aggregate shareholding from 34.82% (3,71,30,124 shares) to 0.01% (8,100 shares). The transaction formally transfers operational and managerial control to the incoming acquirers under SEBI Listing Regulations.
Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 28, 2026 relating to the consummation of the transaction contemplated in the share purchase agreement dated May 23, 2026
Outcome · 29 Sept 2026, 2:19 am
Anupam Rasayan Acquires Controlling 47.95% Stake in Bliss GVS Pharma Anupam Rasayan India Limited, alongside PAC Mates Visa Consultancy, acquired control of Bliss GVS Pharma Ltd. on 28th Sep'26, becoming the new promoters. Following the SPA consummation and open offer, the group holds 5,09,86,264 equity shares, representing 47.95% of total share capital. Concurrently, Managing Director Narsimha Shibroor Kamath resigned from his role and board positions. The board approved the appointments of Hetul Krishnakant Mehta, Amar Dilip Shah, and Pramod Badrinarayan Kasat as Non-Executive Non-Independent Directors, subject to shareholder approval via postal ballot.
Please find enclosed herewith the Outcome of the 1st Board Meeting held on September 28, 2026 at shorter Notice pursuant to the consummation of the transaction contemplated in the share ....
Outcome · 29 Sept 2026, 2:18 am
Please find enclosed herewith the Outcome of the Board Meeting held on September 28, 2026 pursuant to the Change in Control of the Company.
Change in Management · 29 Sept 2026, 2:02 am
Anupam Rasayan and PAC Acquire Control of Bliss GVS Pharma Anupam Rasayan India Ltd., alongside PAC Mates Visa Consultancy Pvt. Ltd., completed the acquisition of 5,09,86,264 equity shares representing a 47.95% stake in Bliss GVS Pharma Ltd. via SPA and an Open Offer on 28th Sep'26, officially assuming promoter status and management control. Concurrently, Managing Director Narsimha Shibroor Kamath resigned from the board. In addition, Hetul Krishnakant Mehta, Amar Dilip Shah, and Pramod Badrinarayan Kasat were appointed as Non-Executive Non-Independent Additional Directors, subject to shareholder approval via postal ballot.
We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held on today i.e. September 04, 2026 has approved the allotment of 55,250 equity shares of ....
Others (Uncategorized) · 05 Sept 2026, 12:20 am
Bliss GVS Pharma Allots 55,250 Equity Shares Under ESOP 2019 Scheme Bliss GVS Pharma Limited's ESOP Allotment Committee approved the allotment of 55,250 equity shares (face value Re. 1 each) on 4th Sep'26 following option exercises under the Bliss GVS ESOP-2019 plan. The shares were issued at an exercise price of Rs. 43 per share, including a premium of Rs. 42 per share, subject to a six-month lock-in period expiring 3rd Mar'27. Consequently, the company's paid-up equity share capital increased from Rs. 10,62,75,223 to Rs. 10,63,30,472, comprising 10,63,30,472 equity shares ranking pari passu with existing shares.
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post-Offer Advertisement in accordance with Regulation 18(12) of the Securities and Exchange Board of ....
Others (Uncategorized) · 02 Sept 2026, 3:38 pm
Please find enclosed herewith the outcome of Members of the Nomination and Remuneration Committee of Bliss GVS Pharma Limited ("the Company")in its meeting held today i.e. on August 12, ....
Others (Uncategorized) · 13 Aug 2026, 1:33 am
Bliss GVS Pharma Grants 320,000 ESOPs at Significant Discount Bliss GVS Pharma’s Nomination and Remuneration Committee granted 320,000 stock options on 12 Aug'26 under its ESOP Plan 2019. The exercise price is set at ₹43 per share, representing a 91.32% discount to the BSE closing price on 11 Aug'26. Options will vest in four equal annual installments of 25% each, starting 12 months from the grant date. Vested options are exercisable within six months, and the resulting equity shares will have a six-month lock-in period from the date of allotment.
We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") with ....
Financial Result · 13 Aug 2026, 1:24 am
Bliss GVS Pharma Q1FY27: Strong YoY Profit Growth and Board Updates Bliss GVS Pharma reported robust Q1FY27 consolidated results with Net Profit up 39.2% YoY to ₹51.4 cr on revenue of ₹285.6 cr, a 16.9% YoY increase. Standalone profit grew 83.4% YoY to ₹38.6 cr. The Board approved the results for the quarter ended 30 Jun'26 and a postal ballot for the appointment of Mr. Santosh Parab as a Non-Executive Non-Independent Director. The auditors issued a limited review report with an unmodified conclusion. The meeting occurred on 12 Aug'26.